Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 89

Sort by

Sort Order Select

Journal Articles

Hi-c FFPE sequencing analysis is highly concordant with FISH and detects additional variants informing diagnosis and treatment in diffuse large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 3529.

https://doi.org/10.1182/blood-2025-3529

Published: 2025

Journal Articles

Cell differentiation stage drives mechanisms of apoptosis evasion in Waldenström macroglobulinemia

Cristina Frusteri, Aleix Real, Ferran Nadeu, Laura Fumagalli, Valentina Manconi, Ali Jafari Kia, Eleonora Terrabuio, Alessio Montresor, Maria Pia Manto, Eleonora Gugole, Angela Mercuri, Laura Bonaldi, Gabriela Constantin, Mauro Krampera, Carlo Visco, Maria Teresa Scupoli, Carlo Laudanna, Isacco Ferrarini

Blood (2025) 146 (Supplement 1): 1774.

https://doi.org/10.1182/blood-2025-1774

Published: 2025

Journal Articles

Real world use of sutimlimab in patients with cold agglutinin disease: An international study

Blood (2025) 146 (Supplement 1): 1100.

https://doi.org/10.1182/blood-2025-1100

Published: 2025

Journal Articles

SGR-1505, a potent and selective MALT1 inhibitor with preliminary efficacy in BTKi exposed Waldenström macroglobulinemia (WM) and “double-exposed” CLL/SLL

Blood (2025) 146 (Supplement 1): 3603.

https://doi.org/10.1182/blood-2025-3603

Published: 2025

Journal Articles

Cytoplasmic but not nuclear cleaved gsdmd expression in live macrophages and DLBCL cells marks proinflammatory cognate interactions rather than pyroptosis and predicts better patient survival in DLBCL

Blood (2025) 146 (Supplement 1): 7079.

https://doi.org/10.1182/blood-2025-7079

Published: 2025

Journal Articles

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study

Meghan Thompson, Annamaria Frustaci, John Seymour, John Allan, Paolo Ghia, Olivier Dumas, Franck Morschhauser, Martin Dreyling, Stephan Stilgenbauer, Inhye Ahn, Romain Guieze, Yanan Zhang, Linlin Xu, Kunthel By, Shannon Fabre, Daniel Persky, Amit Agarwal, Carlo Visco

Blood (2025) 146 (Supplement 1): 3895.

https://doi.org/10.1182/blood-2025-3895

Published: 2025

Journal Articles

First-in-human, open-label, Phase 1 study of a novel CD30-directed antibody-drug conjugate with a topoisomerase 1 inhibitor payload, PF-08046044 (35C), in patients with Relapsed/Refractory lymphomas: Updated safety, PK, preliminary efficacy and ctdna analysis from dose escalation

Swetha Thiruvengadam, Christina Poh, Ryan Lynch, Craig Moskowitz, Michael Spinner, Martin Hutchings, Cristina García Herce, Elizabeth Phillips, Aung Tun, Julie Vose, Mina Nayeri, Erika Rudnicki, Maria Delioukina, Michelle Fanale, Sujit Biswas, Hailing Lu, Carlo Visco

Blood (2025) 146 (Supplement 1): 155.

https://doi.org/10.1182/blood-2025-155

Published: 2025

Journal Articles

Survival after First Relapse in Marginal Zone Lymphomas: Prospective Data from the International Observational NF10 Study By the Fondazione Italiana Linfomi

Blood (2024) 144 (Supplement 1): 1639.

https://doi.org/10.1182/blood-2024-207886

Published: 2024

Journal Articles

Trial in Progress: A Phase II Trial to Investigate Venetoclax in Combination with Ibrutinib and Rituximab or Conventional Chemoimmunotherapy (Bendamustine and Rituximab) and Ibrutinib in Patients with Treatment-Naive Mantle Cell Lymphoma Not Eligible for High-Dose Therapy - MCL Elderly III

Stephanie Herold, Anke Ohler, Marie-Kristin Tilch, Christian Schmidt, Michael Unterhalt, Eva Hoster, Elisabeth Hoenig, Susanne Singer, Carlo Visco, Marco Ladetto, Alessandra Tucci, Christiane Pott, Georg Hess, Martin Dreyling

Blood (2024) 144 (Supplement 1): 3042.2.

https://doi.org/10.1182/blood-2024-204691

Published: 2024

Journal Articles

TP53 , CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial

Blood (2024) 144 (Supplement 1): 1577.

https://doi.org/10.1182/blood-2024-198076

Published: 2024

Journal Articles

Hepatitis C Virus and Hepatitis B Virus in Indolent Lymphomas: Prospective Data from the International Observational NF10 Study

Blood (2024) 144 (Supplement 1): 3020.

https://doi.org/10.1182/blood-2024-207163

Published: 2024

Journal Articles

Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

Blood (2024) 144 (Supplement 1): 4362.

https://doi.org/10.1182/blood-2024-203004

Published: 2024

Journal Articles

Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma

Blood (2024) 144 (Supplement 1): 4361.

https://doi.org/10.1182/blood-2024-201598

Published: 2024

Journal Articles

More is not always better

Carlo Visco

Blood (2024) 144 (10): 1033–1035.

https://doi.org/10.1182/blood.2024025289

Published: 2024

Journal Articles

Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

Blood (2024) 144 (9): 1001–1009.

https://doi.org/10.1182/blood.2023023525

Published: 2024

Includes: Supplemental data

Journal Articles

Real-Life Efficacy and Safety of Vemurafenib Plus Rituximab (V+R) in Relapsed or Refractory Hairy Cell Leukemia: A Multi-Center Retrospective Study (HCL-PG03R)

Blood (2023) 142 (Supplement 1): 3027.

https://doi.org/10.1182/blood-2023-178648

Published: 2023

Journal Articles

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 737.

https://doi.org/10.1182/blood-2023-179169

Published: 2023

Journal Articles

Development of a Novel Prognostic Score in Patients with Waldenström Macroglobulinemia Prospectively Enrolled in the Observational NF10 Study of Fondazione Italiana Linfomi

Blood (2023) 142 (Supplement 1): 3046.

https://doi.org/10.1182/blood-2023-184586

Published: 2023

Journal Articles

Tumor-Infiltrating Normal B Lymphocytes Have Remarkable Prognostic Effects and Are Crucial for Antitumor Immune Responses in Diffuse Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 429.

https://doi.org/10.1182/blood-2023-179972

Published: 2023

Journal Articles

Diffuse Large B-Cell Lymphoma Has a Low Frequency of dMMR and High Frequencies of DNA Mismatch Repair Protein High Expression Associated with Lower T-Cell Infiltration

Blood (2023) 142 (Supplement 1): 6079.

https://doi.org/10.1182/blood-2023-178366

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Hi-c FFPE sequencing analysis is highly concordant with FISH and detects additional variants informing diagnosis and treatment in diffuse large B-cell lymphoma

Cell differentiation stage drives mechanisms of apoptosis evasion in Waldenström macroglobulinemia

Real world use of sutimlimab in patients with cold agglutinin disease: An international study

SGR-1505, a potent and selective MALT1 inhibitor with preliminary efficacy in BTKi exposed Waldenström macroglobulinemia (WM) and “double-exposed” CLL/SLL

Cytoplasmic but not nuclear cleaved gsdmd expression in live macrophages and DLBCL cells marks proinflammatory cognate interactions rather than pyroptosis and predicts better patient survival in DLBCL

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study

First-in-human, open-label, Phase 1 study of a novel CD30-directed antibody-drug conjugate with a topoisomerase 1 inhibitor payload, PF-08046044 (35C), in patients with Relapsed/Refractory lymphomas: Updated safety, PK, preliminary efficacy and ctdna analysis from dose escalation

Survival after First Relapse in Marginal Zone Lymphomas: Prospective Data from the International Observational NF10 Study By the Fondazione Italiana Linfomi

Trial in Progress: A Phase II Trial to Investigate Venetoclax in Combination with Ibrutinib and Rituximab or Conventional Chemoimmunotherapy (Bendamustine and Rituximab) and Ibrutinib in Patients with Treatment-Naive Mantle Cell Lymphoma Not Eligible for High-Dose Therapy - MCL Elderly III

TP53 , CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial

Hepatitis C Virus and Hepatitis B Virus in Indolent Lymphomas: Prospective Data from the International Observational NF10 Study

Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma

More is not always better

Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

Real-Life Efficacy and Safety of Vemurafenib Plus Rituximab (V+R) in Relapsed or Refractory Hairy Cell Leukemia: A Multi-Center Retrospective Study (HCL-PG03R)

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Development of a Novel Prognostic Score in Patients with Waldenström Macroglobulinemia Prospectively Enrolled in the Observational NF10 Study of Fondazione Italiana Linfomi

Tumor-Infiltrating Normal B Lymphocytes Have Remarkable Prognostic Effects and Are Crucial for Antitumor Immune Responses in Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma Has a Low Frequency of dMMR and High Frequencies of DNA Mismatch Repair Protein High Expression Associated with Lower T-Cell Infiltration

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only